Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance

Rajandram, Retnagowri; Yap, Ning Yi; Pailoor, Jayalakshmi; Razack, Azad Hassan Abdul; Ng, Ka Ying Bonnie; Ong, Teng Aik; Morais, Christudas; Gobé, Glenda C.

doi:10.1097/pat.0000000000000145

Cited by 13 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC cases are frequently incidentally diagnosed during the imaging examination for nonspecific symptoms or other abdominal disease, which now accounts for half of all new RCC cases [9]. Some reports have identified that molecules such as TRAF-1 [10], Hsp27 [11], MMPs [12] or NMP-22 [13], which exhibit altered levels in serum or urine in RCC patients, may provide useful diagnostic information. However, no standardized serum or urine Therefore, a more efficient diagnosis technique or a biomarker is urgently needed.…”

Section: Discussionmentioning

confidence: 99%

Saliva proteomic analysis reveals possible biomarkers of renal cell carcinoma

Zhang

et al. 2020

Open Chemistry

View full text Add to dashboard Cite

Early diagnosis is a key to improve the prognosis of renal cell carcinoma (RCC); however, reliable RCC biomarkers are lacking in clinical practice. In this study, we used isobaric tags for relative and absolute quantification-based mass spectrometry to identify salivary proteins as biomarkers for the diagnosis of RCC. The objective of this study is to discover biomarkers from saliva by utilizing high-throughput quantitative proteomics approaches. Saliva proteins from 124 RCC patients and healthy individuals were identified and quantified. RCC putative biomarkers were verified by real-time polymerase chain reaction or enzyme-linked immunosorbent assay in a prevalidation sample set. Seventy-one differentially expressed salivary proteins were identified. Serotransferrin, haptoglobin, KRT9, and S100A9, which in previous studies were found to be most closely related to cancers, were selected as putative RCC biomarkers. Haptoglobin and S100A9 were significantly elevated in RCC compared with healthy control samples, although the expression of serotransferrin and KRT9 did not differ between the groups. Furthermore, receiver operating characteristic curves with a cut-off value of 75.49 ng/mL for S100A9 revealed a sensitivity of 87.10% and a specificity of 91.94% for discriminating RCC patients from healthy individuals. Salivary haptoglobin differentiated RCC patients from healthy controls with a sensitivity of 85.48% and specificity of 80.65% (cut-off value 43.02 µg/mL). These results provide experimental evidence to support S100A9 and haptoglobin as potential novel, noninvasive biomarkers for the diagnosis of RCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Saliva proteomic analysis reveals possible biomarkers of renal cell carcinoma

Zhang

et al. 2020

Open Chemistry

View full text Add to dashboard Cite

show abstract

“…Currently, there are no available biomarkers for an accurate diagnosis of RCC. In certain studies, molecules that are measurable in serum have been reported (8). Immunological tests including ELISA or mass spectrometry have been used to identify altered proteins in RCC patients and can provide valuable information regarding prognosis and diagnosis.…”

Section: Renal Tumor Biomarkers (Review)mentioning

confidence: 99%

Renal tumor biomarkers (Review)

et al. 2021

View full text Add to dashboard Cite

One of the most common types of cancer worldwide (9th most commonly diagnosed) is renal cell carcinoma (RCC). It is more common in developed countries and it usually develops in individuals between 60 and 70 years of age. The earlier the disease is identified, the lower the morbidity. Therefore molecular markers that exist in blood and urine may be used for earlier detection and diagnosis but also for the follow-up of the patient after treatment, whether surgical or oncological. The trend is to analyze the gene and protein expression as they constitute a source for new biomarkers. These markers are promising but in clinical practice regarding disease management, they are rarely used. Biological markers can be employed in many tumors because they can identify the prognostic value for individual treatment. However, markers for RCC are not validated, and their analysis is currently under investigation. Previous findings have demonstrated that the metastatic potential of RCC can be predicted using the biological features of the tumor cell. It is believed that the transformation from epithelial to mesenchymal phenotype gives the tumor cell the ability to metastasize. The purpose of this review was to identify the most valuable tumor markers that can be clinically used for the prognosis, treatment and follow-up of patients with renal tumors.

show abstract

“…TRAF-1 is an adaptor protein involved in the regulation of cell survival, proliferation, differentiation, and stress responses. It has been reported that serum levels of TRAF-1 in RCC patients were significantly increased over control serum [ 51 ].…”

Section: Molecular Biomarkersmentioning

confidence: 99%

Serum and Urine Biomarkers for Human Renal Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) diagnosis is mostly achieved incidentally by imaging provided for unrelated clinical reasons. The surgical management of localized tumors has reported excellent results. The therapy of advanced RCC has evolved considerably over recent years with the widespread use of the so-called “targeted therapies.” The identification of molecular markers in body fluids (e.g., sera and urine), which can be used for screening, diagnosis, follow-up, and monitoring of drug-based therapy in RCC patients, is one of the most ambitious challenges in oncologic research. Although there are some promising reports about potential biomarkers in sera, there is limited available data regarding urine markers for RCC. The following review reports some of the most promising biomarkers identified in the biological fluids of RCC patients.

show abstract

Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance

Cited by 13 publications

References 42 publications

Saliva proteomic analysis reveals possible biomarkers of renal cell carcinoma

Saliva proteomic analysis reveals possible biomarkers of renal cell carcinoma

Renal tumor biomarkers (Review)

Serum and Urine Biomarkers for Human Renal Cell Carcinoma

Contact Info

Product

Resources

About